MSB2311 is a 2nd generation PD-L1 antibody with a unique pH-dependent antigen binding property that enables intra-tumor recycling and potentiates tumor penetration.
It is the first clinical asset generated by MabSpace's proprietary immune tolerance breaking technology platform.
This study, MSB2311-CSP-001, is a first-in-human, open-label, Phase 1 dose-escalation study of MSB2311, a humanized anti-PD-L1 monoclonal antibody in patients with advanced solid tumors.
A separate China Phase 1 study with several disease expansion cohorts to evaluate preliminary efficacy is at the final stage of regulatory review, and if approved, is expected to be initiated soon.
MabSpace Biosciences specializes in discovering and developing innovative antibody therapeutics using its proprietary immune tolerance breaking technology platform.
The company has built a pipeline in immune-oncology, ophthalmology, and nephrology. It is headquartered in Hong Kong, with a fully-integrated antibody discovery and development facility in Biobay, Suzhou Industrial Park, China.
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amgen and Kyowa Kirin release rocatinlimab study results in atopic dermatitis
Hemogenyx Pharmaceuticals partners with Made Scientific to advance CAR-T therapy
Lilly's Jaypirca delivers breakthrough results in front-line CLL trial